suggested remit: To appraise the clinical and cost effectiveness of ripretinib within its marketing authorisation for advanced gastrointestinal stromal tumours (GIST) who have received previous treatment with tyrosine kinase inhibitors (TKI).
 
Status In progress
Decision Selected
Process TAG
ID number 3805

Provisional Schedule

Committee meeting: 1 02 November 2022
Expected publication 25 January 2023

Project Team

Project lead Kate Moore

Email enquiries

Stakeholders

Companies sponsors Deciphera Pharmaceuticals (ripretinib)
Others Department of Health and Social Care
  NHS England
  NHS Fareham and Gosport CCG
  NHS North West Surrey CCG
  Welsh Government
Patient carer groups Barrett’s Oesophagus Campaign
  Black Health Agency for Equality
  Bladder and Bowel Community
  Bowel Cancer Information
  Bowel Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  GIST Cancer UK
  Guts UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Oesophageal Patients Association
  Sarcoma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Coloproctology of Great Britain and Ireland
  Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Sarcoma Group
  British Society of Gastroenterology
  Cancer Research UK
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Scottish Sarcoma Network
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health England
  Public Health Wales
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee
Relevant research groups Bowel Research UK
  Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  Foundation for Liver research
  GASTROCAN
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
18 November 2021 The timelines for this appraisal moving forward have now been confirmed. The deadline for evidence submission is Tuesday 17 May 2022. The first appraisal committee meeting discussion will now be held on 2 November 2022.
18 November 2021 In progress. The timelines for this appraisal moving forward have now been confirmed. The deadline for evidence submission is Tuesday 17 May 2022. The first appraisal committee meeting discussion will now be held on 2 November 2022.
17 September 2021 Suspended. The company, Deciphera Pharmaceuticals, has been in touch with NICE to request a delay to the submission. As a consequence, the appraisal committee meeting originally scheduled for 10 March 2022 has been cancelled. This appraisal will be suspended whilst we agree new timelines with the company. A further update will be provided in due course.
08 July 2021 Invitation to participate
26 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of ripretinib within its marketing authorisation for treating advanced gastrointestinal stromal tumours after 3 therapies. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-July 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
07 January 2021 - 04 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual